adamantane has been researched along with Cancer of Kidney in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drake, RR; Gao, P; Jones, EE; Norris, JS; Smith, CD | 1 |
| Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
2 other study(ies) available for adamantane and Cancer of Kidney
| Article | Year |
|---|---|
Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow.
Topics: Adamantane; Animals; Biomarkers, Tumor; Ceramides; Disease Models, Animal; Humans; Kidney Neoplasms; Lysophospholipids; Mice; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Sphingosine; Transplantation, Heterologous | 2015 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |